New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:45 EDTSRPTLeerink still cautious on FDA approving eteplirsen with existing data
Leerink says it continues to have reservations that the FDA will approve Sarepta's eteplirsen on its existing data set. The firm thinks today's news supports its belief that the FDA is "kicking the can down the road" on an eteplirsen decision until it obtains more analyzed data. Leerink reiterates a Market Perform rating on Sarepta with a $31 price target.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
10:32 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: ESPR SRPT CX RAX YY SPLK QIHU HFC OWW BBY
July 29, 2015
06:38 EDTSRPTBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 28, 2015
10:38 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
July 27, 2015
10:40 EDTSRPTIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 22, 2015
17:06 EDTSRPTSarepta announce publication of Phase I clinical data of AVI-7288
Subscribe for More Information
July 20, 2015
14:32 EDTSRPTFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTSRPTSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
10:13 EDTSRPTOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use